Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosomes promote pre-metastatic niche formation in ovarian cancer

Feng W., Dean DC., Hornicek FJ., Shi H., Duan Z.

Narrative Review on Immune Modulation, published in Mol Cancer (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mol Cancer (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31409361
PMCID
PMC6691526
DOI
10.1186/s12943-019-1049-4
Citations
229

Abstract (original English)

Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a pre-metastatic niche occurring prior to macroscopic tumor cell invasion. Exosomes released by the primary ovarian tumor are small extracellular vesicles which prepare the distant tumor microenvironment for accelerated metastatic invasion. They regulate intercellular communication between tumor cells and normal stroma, cancer-associated fibroblasts, and local immune cells within the tumor microenvironment. In this review, we highlight the emerging roles of ovarian cancer exosomes as coordinators of pre-metastatic niche formation, biomarkers amenable to liquid biopsy, and targets of chemotherapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MacrophagesAnimalsHumansOvarian NeoplasmsNeoplasm MetastasisNeovascularization, PathologicNeoplasm StagingFemaleExosomesImmunomodulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research